Health X Platform cash flow

Latest FY26

Cash from operations: −₹73.8cr−₹17.3 cr in FY25
Capital spending: ₹14.9cr+44.2% on FY25
Free cash flow: −₹88.8cr−₹27.7 cr in FY25
Cash from financing: −₹79.6cr−₹0.4 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	6.6	5.8	9.1	8.2
	—	0.8	0.2	1.0	0.9
	—	−16.8	−15.1	−22.8	−19.1
	—	−1.8	−0.3	−0.2	−0.1
	—	−19.3	−21.9	−32.7	−1.8
	—	4.0	−0.3	5.0	11.2
	—	−29.8	−31.7	−19.9	−0.1
	—	0.0	191	0.0	0.0
	—	−34.4	5.5	65.0	−67.3
	—	1.8	20.3	−11.1	−25.1
	—	3.9	0.0	−2.0	−3.3
	—	0.0	1.9	−0.3	1.7
	—	0.0	0.0	8.3	−17.0
	—	−16.8	0.0	0.0	0.0
	—	0.0	26.9	0.0	0.0
	—	28.1	0.0	−14.1	23.9
	—	2.6	2.8	2.1	4.8
	—	0.0	0.0	0.0	7.5
	—	0.0	−4.0	1.6	4.7
	—	4.2	0.0	0.0	0.0
	—	−0.4	−0.8	−0.5	−0.1
	—	0.0	0.0	0.0	0.0
Cash from operating activities
	−30.6	−2.4	−193	55.7	−37.4
	—	−67.1	180	−11.4	−71.1
	—	−69.5	−12.9	44.3	−108
	—	4.3	4.5	6.1	−4.0
	—	−73.8	−17.3	38.2	−104
Cash from investing activities
	—	14.9	10.4	14.2	27.9
	—	0.1	0.3	0.6	3.3
	—	0.0	0.0	0.0	402
	—	0.0	0.0	0.0	493
	—	0.0	0.0	898	0.0
	—	0.0	0.0	697	0.0
	—	704	708	0.0	0.0
	—	801	662	0.0	0.0
	—	0.0	0.0	0.0	0.0
	—	1.8	0.3	0.2	0.1
	—	11.3	11.8	21.7	21.1
	—	76.0	42.4	158	35.9
	—	171	−1.1	−33.9	124
Cash from financing activities
	—	100	0.0	0.0	0.0
	—	22.1	0.0	0.0	0.0
	—	1.1	0.4	2.3	0.0
	—	0.6	0.1	0.1	0.9
	—	−79.6	−0.4	−2.4	−0.9
	—	17.8	−18.9	1.9	18.7
	—	17.8	−18.9	1.9	18.7
	—	—	—	33.6	31.7
Reference items
	−66.5	−52.1	−56.0	5.4	−44.0
	−4.5%	−4.0%	−5.0%	0.4%	−4.2%
	−88.8	−88.8	−27.7	23.9	−132
	—	−67.3	−27.7	23.9	—
	−₹27.90	−₹27.90	−₹8.70	₹7.52	−₹41.63
	—	51.01×	0.13×	6.52×	1.05×
	—	4.3	4.5	6.1	−4.0
	—	0.6	0.1	0.1	0.9

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HEALTHX₹279.20

Health X Platform Limited

· Pharma & Health

₹ CrorePeersSURAKSHA KRSNAA NEPHROPLUS 3BBLACKBIOMcap ₹888 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	8.2	9.1	5.8	6.6	—
+ Finance Costs	0.9	1.0	0.2	0.8	—
+ Interest Income	-19.1	-22.8	-15.1	-16.8	—
+ Dividend Income	-0.1	-0.2	-0.3	-1.8	—
+ Fair Value (Gains) / Losses	-1.8	-32.7	-21.9	-19.3	—
+ Other Non-cash Items	11.2	5.0	-0.3	4.0	—
+ Other — Cash Effects are Investing / Financing	-0.1	-19.9	-31.7	-29.8	—
+ Other Reconciling Items	0.0	0.0	190.6	0.0	—
Changes in Working Capital
+ Inventories	-67.3	65.0	5.5	-34.4	—
+ Trade Receivables — Current	-25.1	-11.1	20.3	1.8	—
+ Other Financial Assets — Current	-3.3	-2.0	0.0	3.9	—
+ Other Financial Assets — Non-current	1.7	-0.3	1.9	0.0	—
+ Other Current Assets	-17.0	8.3	0.0	0.0	—
+ Other Non-current Assets	0.0	0.0	0.0	-16.8	—
+ Other Bank Balances	0.0	0.0	26.9	0.0	—
+ Trade Payables — Current	23.9	-14.1	0.0	28.1	—
+ Other Financial Liabilities — Current	4.8	2.1	2.8	2.6	—
+ Other Financial Liabilities — Non-current	7.5	0.0	0.0	0.0	—
+ Other Current Liabilities	4.7	1.6	-4.0	0.0	—
+ Other Non-current Liabilities	0.0	0.0	0.0	4.2	—
+ Provisions — Current	-0.1	-0.5	-0.8	-0.4	—
+ Provisions — Non-current	0.0	0.0	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	-37.4	55.7	-192.9	-2.4	-30.6
+ Total Adjustments (incl. Working Capital)	-71.1	-11.4	180.0	-67.1	—
Cash from Operations (pre-tax)	-108.5	44.3	-12.9	-69.5	—
+ Income Taxes Paid	-4.0	6.1	4.5	4.3	—
Cash from Operating Activities	-104.5	38.2	-17.3	-73.8	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	27.9	14.2	10.4	14.9	—
+ Disp of Fixed Assets	3.3	0.6	0.3	0.1	—
+ Acq of Investment Property	401.8	0.0	0.0	0.0	—
+ Disp of Investment Property	493.3	0.0	0.0	0.0	—
+ Acq of Other Long-term Assets	0.0	897.6	0.0	0.0	—
+ Disp of Other Long-term Assets	0.0	697.2	0.0	0.0	—
+ Purchase of Investments (Equity / Debt)	0.0	0.0	708.0	703.6	—
+ Sale of Investments (Equity / Debt)	0.0	0.0	662.5	800.5	—
+ Disp of Subsidiaries / Businesses (net)	0.0	0.0	0.0	0.0	—
+ Dividends Received — Investing	0.1	0.2	0.3	1.8	—
+ Interest Received — Investing	21.1	21.7	11.8	11.3	—
+ Other Inflows / (Outflows) — Investing	35.9	158.1	42.4	76.0	—
Cash from Investing Activities	124.1	-33.9	-1.1	171.2	—
Cash from Financing Activities
+ Payments — Change in Ownership of Subsidiaries	0.0	0.0	0.0	100.0	—
+ Proceeds from Borrowings	0.0	0.0	0.0	22.1	—
+ Payment of Lease Liabilities	0.0	2.3	0.4	1.1	—
+ Interest Paid	0.9	0.1	0.1	0.6	—
Cash from Financing Activities	-0.9	-2.4	-0.4	-79.6	—
Net Changes in Cash (pre-FX)	18.7	1.9	-18.9	17.8	—
Net Changes in Cash	18.7	1.9	-18.9	17.8	—
Closing Cash	31.7	33.6	—	—	—
Reference Items
EBITDA	-44.0	5.4	-56.0	-52.1	-66.5
EBITDA Margin %	-4.23	0.39	-5.04	-3.95	-4.53
Free Cash Flow (CFO − Capex)	-132.4	23.9	-27.7	-88.8	-88.8
Free Cash Flow to Equity	—	23.9	-27.7	-67.3	—
Free Cash Flow per Basic Share	-41.63	7.52	-8.70	-27.90	-27.90
Cash Flow to Net Income	1.05	6.52	0.13	51.01	—
Cash Paid for Taxes	-4.0	6.1	4.5	4.3	—
Cash Paid for Interest	0.9	0.1	0.1	0.6	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.